LP
CBAY

LMR Partners’s Cymabay Therapeutics CBAY Stock Holding History

LMR Partners’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-66,251
Closed -$578K – 1182
2023
Q1 		$578K Buy
66,251
+25,747
+64% +$206K 0.01% 685
2022
Q4 		$254K Buy
40,504
+10,144
+33% +$38.6K ﹤0.01% 973
2022
Q3 		$106K Hold
30,360
– – ﹤0.01% 1048
2022
Q2 		$90K Buy
+30,360
New +$72.5K ﹤0.01% 1108
2020
Q1 		– Sell
-890,894
Closed -$1.75K – 468
2019
Q4 		$1.75K Buy
+890,894
New +$3.35M ﹤0.01% 144

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

LMR Partners's CBAY Position: Q2 2023 in Review

LMR Partners sold out of Cymabay Therapeutics (CBAY) in Q2 2023, closing a stake of 66,251 shares — an estimated $578K sold.

LMR Partners first reported a position in CBAY in Q4 2019 and held it in 5 quarters. The position peaked at $578K in Q1 2023. 151 funds tracked by Wall St. Rank hold CBAY as of Q2 2023.

  • LMR Partners reported no remaining Cymabay Therapeutics position as of Q2 2023 after selling out during the quarter.
  • LMR Partners sold 66,251 Cymabay Therapeutics shares in Q2 2023, an estimated $578K.
  • LMR Partners first reported a position in Cymabay Therapeutics in Q4 2019 and held it in 5 quarters.
  • LMR Partners's Cymabay Therapeutics position peaked at $578K in Q1 2023.
  • 151 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q2 2023.

Based on LMR Partners's 13F filing for Q2 2023, filed 14 Aug 2023.